Top

Published in:

01-01-2021 | Breast Cancer | Epidemiology

Family history of breast cancer in men with non-BRCA male breast cancer: implications for cancer risk counseling

Authors: Gregory S. Calip, John Kidd, Ryan Bernhisel, Hannah C. Cox, Jennifer Saam, Garth H. Rauscher, Johnathan M. Lancaster, Kent F. Hoskins

Published in: Breast Cancer Research and Treatment | Issue 1/2021

Abstract

Purpose

The role of genetic predisposition in male breast cancer (MBC) patients who test negative for a BRCA mutation is unclear. The aim of this study is to define the association between MBC and family history of breast cancer in patients without mutations in BRCA1 or BRCA2.

Methods

We conducted an unmatched case–control study with men who received commercial testing for germline mutations in cancer susceptibility genes, including 3,647 MBC cases who tested negative for deleterious mutations in BRCA1/BRCA2, and 4,269 men with a personal history of colorectal cancer who tested negative for mutations in DNA mismatch repair genes to serve as controls. Associations between family history of breast cancer and MBC were estimated using unconditional multivariable logistic regression with adjustment for age, race/ethnicity and year of testing.

Results

Breast cancer in a first- or second-degree relative was associated with a four-fold increased odds of MBC (OR 4.7; 95% CI 4.1, 5.3). Associations with MBC were strongest for family history of breast cancer in 2 or more first-degree relatives (FDR) (OR 7.8; 95% CI 5.2, 11.6), for probands and FDR diagnosed at age < 45 years (OR 6.9; 95% CI 3.9, 12.4), and for family history of MBC (OR 17.9; 95% CI 7.6, 42.1). Findings were confirmed in a sensitivity analysis of MBC cases who tested negative on a 25-gene pan-cancer panel.

Conclusions

MBC patients without mutations in BRCA1/2 have significantly higher odds of a family history of breast cancer, suggesting the existence of unidentified MBC susceptibility alleles.

Available only for authorised users

American Cancer Society Breast Cancer Facts & Figures 2019–2020. Atlanta: American Cancer Society, Inc. 2019.

Anderson WF, Althuis MD, Brinton LA, Devesa SS (2004) Is male breast cancer similar or different than female breast cancer? Breast Cancer Res Treat 83(1):77–86. https://doi.org/10.1023/B:BREA.0000010701.08825.2dCrossRefPubMed

Ruddy KJ, Winer EP (2013) Male breast cancer: risk factors, biology, diagnosis, treatment, and survivorship. Ann Oncol 24(6):1434–1443. https://doi.org/10.1093/annonc/mdt025CrossRefPubMed

Ferzoco RM, Ruddy KJ (2016) The epidemiology of male breast cancer. Curr Oncol Rep 18(1):1. https://doi.org/10.1007/s11912-015-0487-4CrossRefPubMed

Giordano SH, Buzdar AU, Hortobagyi GN (2002) Breast cancer in men. Ann Intern Med 137(8):678–687CrossRef

Brinton LA, Richesson DA, Gierach GL, Lacey JV Jr, Park Y, Hollenbeck AR, Schatzkin A (2008) Prospective evaluation of risk factors for male breast cancer. J Natl Cancer Inst 100(20):1477–1481. https://doi.org/10.1093/jnci/djn329CrossRefPubMedPubMedCentral

Rosenblatt KA, Thomas DB, McTiernan A, Austin MA, Stalsberg H, Stemhagen A, Thompson WD, Curnen MG, Satariano W, Austin DF et al (1991) Breast cancer in men: aspects of familial aggregation. J Natl Cancer Inst 83(12):849–854CrossRef

Evans DG, Susnerwala I, Dawson J, Woodward E, Maher ER, Lalloo F (2010) Risk of breast cancer in male BRCA2 carriers. J Med Genet 47(10):710–711. https://doi.org/10.1136/jmg.2009.075176CrossRefPubMed

Tai YC, Domchek S, Parmigiani G, Chen S (2007) Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 99(23):1811–1814. https://doi.org/10.1093/jnci/djm203CrossRefPubMedPubMedCentral

10.

Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory S, Gumbs C, Micklem G (1995) Identification of the breast cancer susceptibility gene BRCA2. Nature 378(6559):789–792. https://doi.org/10.1038/378789a0CrossRefPubMed

11.

Basham VM, Lipscombe JM, Ward JM, Gayther SA, Ponder BA, Easton DF, Pharoah PD (2002) BRCA1 and BRCA2 mutations in a population-based study of male breast cancer. Breast Cancer Res 4(1):R2CrossRef

12.

Couch FJ, Farid LM, DeShano ML, Tavtigian SV, Calzone K, Campeau L, Peng Y, Bogden B, Chen Q, Neuhausen S, Shattuck-Eidens D, Godwin AK, Daly M, Radford DM, Sedlacek S, Rommens J, Simard J, Garber J, Merajver S, Weber BL (1996) BRCA2 germline mutations in male breast cancer cases and breast cancer families. Nat Genet 13(1):123–125. https://doi.org/10.1038/ng0596-123CrossRefPubMed

13.

Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Fan I, Tang J, Li S, Zhang S, Shaw PA, Narod SA (2006) Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario Canada. J Natl Cancer Inst 98(23):1694–1706. https://doi.org/10.1093/jnci/djj465CrossRefPubMed

14.

Chen S, Parmigiani G (2007) Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 25(11):1329–1333. https://doi.org/10.1200/JCO.2006.09.1066CrossRefPubMedPubMedCentral

15.

Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tulinius H, Thorlacius S, Eerola H, Nevanlinna H, Syrjakoski K, Kallioniemi OP, Thompson D, Evans C, Peto J, Lalloo F, Evans DG, Easton DF (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72(5):1117–1130. https://doi.org/10.1086/375033CrossRefPubMedPubMedCentral

16.

Wasielewski M, den Bakker MA, van den Ouweland A, Meijer-van Gelder ME, Portengen H, Klijn JG, Meijers-Heijboer H, Foekens JA, Schutte M (1100delC) CHEK2 1100delC and male breast cancer in the Netherlands. Breast Cancer Res Treat 116(2):397–400. https://doi.org/10.1007/s10549-008-0162-7CrossRefPubMed

17.

Meijers-Heijboer H, van den Ouweland A, Klijn J, Wasielewski M, de Snoo A, Oldenburg R, Hollestelle A, Houben M, Crepin E, van Veghel-Plandsoen M, Elstrodt F, van Duijn C, Bartels C, Meijers C, Schutte M, McGuffog L, Thompson D, Easton D, Sodha N, Seal S, Barfoot R, Mangion J, Chang-Claude J, Eccles D, Eeles R, Evans DG, Houlston R, Murday V, Narod S, Peretz T, Peto J, Phelan C, Zhang HX, Szabo C, Devilee P, Goldgar D, Futreal PA, Nathanson KL, Weber B, Rahman N, Stratton MR, Consortium CH-BC (2002) Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 31(1):55–59. https://doi.org/10.1038/ng879CrossRefPubMed

18.

Silvestri V, Rizzolo P, Falchetti M, Zanna I, Masala G, Bianchi S, Palli D, Ottini L (2011) Mutation analysis of BRIP1 in male breast cancer cases: a population-based study in Central Italy. Breast Cancer Res Treat 126(2):539–543. https://doi.org/10.1007/s10549-010-1289-xCrossRefPubMed

19.

Silvestri V, Zelli V, Valentini V, Rizzolo P, Navazio AS, Coppa A, Agata S, Oliani C, Barana D, Castrignano T, Viel A, Russo A, Tibiletti MG, Zanna I, Masala G, Cortesi L, Manoukian S, Azzollini J, Peissel B, Bonanni B, Peterlongo P, Radice P, Palli D, Giannini G, Chillemi G, Montagna M, Ottini L (2017) Whole-exome sequencing and targeted gene sequencing provide insights into the role of PALB2 as a male breast cancer susceptibility gene. Cancer 123(2):210–218. https://doi.org/10.1002/cncr.30337CrossRefPubMed

20.

Silvestri V, Rizzolo P, Zanna I, Falchetti M, Masala G, Bianchi S, Papi L, Giannini G, Palli D, Ottini L (2010) PALB2 mutations in male breast cancer: a population-based study in Central Italy. Breast Cancer Res Treat 122(1):299–301. https://doi.org/10.1007/s10549-010-0797-zCrossRefPubMed

21.

Ding YC, Steele L, Kuan CJ, Greilac S, Neuhausen SL (2011) Mutations in BRCA2 and PALB2 in male breast cancer cases from the United States. Breast Cancer Res Treat 126(3):771–778. https://doi.org/10.1007/s10549-010-1195-2CrossRefPubMed

22.

Syrjakoski K, Kuukasjarvi T, Auvinen A, Kallioniemi OP (1100delC) CHEK2 1100delC is not a risk factor for male breast cancer population. Int J Cancer 108(3):475–476. https://doi.org/10.1002/ijc.11384CrossRefPubMed

23.

Falchetti M, Lupi R, Rizzolo P, Ceccarelli K, Zanna I, Calo V, Tommasi S, Masala G, Paradiso A, Gulino A, Giannini G, Russo A, Palli D, Ottini L (2008) BRCA1/BRCA2 rearrangements and CHEK2 common mutations are infrequent in Italian male breast cancer cases. Breast Cancer Res Treat 110(1):161–167. https://doi.org/10.1007/s10549-007-9689-2CrossRefPubMed

24.

Apostolou P, Fostira F, Papamentzelopoulou M, Michelli M, Panopoulos C, Fountzilas G, Konstantopoulou I, Voutsinas GE, Yannoukakos D (2015) CHEK2 c.1100delC allele is rarely identified in Greek breast cancer cases. Cancer Genet 208(4):129–134. https://doi.org/10.1016/j.cancergen.2015.02.006CrossRefPubMed

25.

Neuhausen S, Dunning A, Steele L, Yakumo K, Hoffman M, Szabo C, Tee L, Baines C, Pharoah P, Goldgar D, Easton D (2004) Role of CHEK2*1100delC in unselected series of non-BRCA1/2 male breast cancers. Int J Cancer 108(3):477–478. https://doi.org/10.1002/ijc.11385CrossRefPubMed

26.

Pritzlaff M, Summerour P, McFarland R, Li S, Reineke P, Dolinsky JS, Goldgar DE, Shimelis H, Couch FJ, Chao EC, LaDuca H (2017) Male breast cancer in a multi-gene panel testing cohort: insights and unexpected results. Breast Cancer Res Treat 161(3):575–586. https://doi.org/10.1007/s10549-016-4085-4CrossRefPubMed

27.

Mavaddat N, Peock S, Frost D, Ellis S, Platte R, Fineberg E, Evans DG, Izatt L, Eeles RA, Adlard J, Davidson R, Eccles D, Cole T, Cook J, Brewer C, Tischkowitz M, Douglas F, Hodgson S, Walker L, Porteous ME, Morrison PJ, Side LE, Kennedy MJ, Houghton C, Donaldson A, Rogers MT, Dorkins H, Miedzybrodzka Z, Gregory H, Eason J, Barwell J, McCann E, Murray A, Antoniou AC, Easton DF, Embrace (2013) Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst 105(11):812–822. https://doi.org/10.1093/jnci/djt095CrossRefPubMed

28.

Brose MS, Rebbeck TR, Calzone KA, Stopfer JE, Nathanson KL, Weber BL (2002) Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 94(18):1365–1372CrossRef

29.

Anderson DE, Badzioch MD (1992) Breast cancer risks in relatives of male breast cancer patients. J Natl Cancer Inst 84(14):1114–1117CrossRef

30.

Bevier M, Sundquist K, Hemminki K (2012) Risk of breast cancer in families of multiple affected women and men. Breast Cancer Res Treat 132(2):723–728. https://doi.org/10.1007/s10549-011-1915-2CrossRefPubMed

31.

Friedman LS, Gayther SA, Kurosaki T, Gordon D, Noble B, Casey G, Ponder BA, Anton-Culver H (1997) Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population. Am J Hum Genet 60(2):313–319PubMedPubMedCentral

32.

von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP, Initiative S (2008) The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 61(4):344–349. https://doi.org/10.1016/j.jclinepi.2007.11.008CrossRef

33.

Schulz KF, Grimes DA (2002) Case-control studies: research in reverse. Lancet 359(9304):431–434CrossRef

34.

Eggington JM, Bowles KR, Moyes K, Manley S, Esterling L, Sizemore S, Rosenthal E, Theisen A, Saam J, Arnell C, Pruss D, Bennett J, Burbidge LA, Roa B, Wenstrup RJ (2014) A comprehensive laboratory-based program for classification of variants of uncertain significance in hereditary cancer genes. Clin Genet 86(3):229–237. https://doi.org/10.1111/cge.12315CrossRefPubMed

35.

Storm HH, Olsen J (1999) Risk of breast cancer in offspring of male breast-cancer patients. Lancet 353(9148):209. https://doi.org/10.1016/S0140-6736(05)77219-6CrossRefPubMed

36.

Malone KE, Daling JR, Doody DR et al (2006) Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years. Cancer Res 66(16):8297–8308CrossRef

37.

Rose S, Laan MJ (2009) Why match? Investigating matched case-control study designs with causal effect estimation. Int J Biostat. https://doi.org/10.2202/1557-4679.1127CrossRefPubMedPubMedCentral

38.

Kerber RA, Slattery ML (1997) Comparison of self-reported and database-linked family history of cancer data in a case-control study. Am J Epidemiol 146(3):244–248CrossRef

39.

Ramsey SD, Yoon P, Moonesinghe R, Khoury MJ (2006) Population-based study of the prevalence of family history of cancer: implications for cancer screening and prevention. Genet Med 8(9):571–575. https://doi.org/10.1097/01.gim.0000237867.34011.12CrossRefPubMedPubMedCentral

40.

Daly MB, Pilarski R, Yurgelun MB, Berry MP, Buys SS, Dickson P, Domchek SM, Elkhanany A, Friedman S, Garber JE, Goggins M, Hutton ML, Khan S, Klein C, Kohlmann W, Kurian AW, Laronga C, Litton JK, Mak JS, Menendez CS, Merajver SD, Norquist BS, Offit K, Pal T, Pederson HJ, Reiser G, Shannon KM, Visvanathan K, Weitzel JN, Wick MJ, Wisinski KB, Dwyer MA, Darlow SD (2020) NCCN guidelines insights: genetic/familial high-risk assessment: breast, ovarian, and pancreatic, version 1.2020. J Natl Compr Cancer Netw 18(4):380–391. https://doi.org/10.6004/jnccn.2020.0017CrossRef

41.

Johnson KC, Pan S, Mao Y, Canadian Cancer Registries Epidemiology Research G (2002) Risk factors for male breast cancer in Canada, 1994–1998. Eur J Cancer 11(3):253–263. https://doi.org/10.1097/00008469-200206000-00009CrossRef

42.

Ewertz M, Holmberg L, Tretli S, Pedersen BV, Kristensen A (2001) Risk factors for male breast cancer—a case-control study from Scandinavia. Acta Oncol 40(4):467–471. https://doi.org/10.1080/028418601750288181CrossRefPubMed

43.

Rothman KJ, Greenland S, Lash TL (2008) Modern epidemiology, 3rd edn. Wolters Kluwer Health/Lippincott Williams & Wilkins, Philadelphia

Title: Family history of breast cancer in men with non-BRCA male breast cancer: implications for cancer risk counseling
Authors: Gregory S. Calip
John Kidd
Ryan Bernhisel
Hannah C. Cox
Jennifer Saam
Garth H. Rauscher
Johnathan M. Lancaster
Kent F. Hoskins
Publication date: 01-01-2021
Publisher: Springer US
Keywords: Breast Cancer
Breast Cancer
Published in: Breast Cancer Research and Treatment / Issue 1/2021
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-020-05922-w

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Serial single-cell profiling analysis of metastatic TNBC during Nab-paclitaxel and pembrolizumab treatment

FDG-PET/CT in high-risk primary breast cancer—a prospective study of stage migration and clinical impact

Association between body mass index and localization of breast cancer: results from a nationwide inpatient database in Japan

Tumor necrosis by pretreatment breast MRI: association with neoadjuvant systemic therapy (NAST) response in triple-negative breast cancer (TNBC)

Metformin and an insulin/IGF-1 receptor inhibitor are synergistic in blocking growth of triple-negative breast cancer

Telerehabilitation for patients with breast cancer through the COVID-19 pandemic

Keynote webinar | Spotlight on antibody–drug conjugates in cancer